ERS Genomics and medicines discovery catapult sign CRISPR/Cas9 license agreement

Dublin, Ireland, and Cheshire, UK, 04 September 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult (‘MDC’), an independent, not-for-profit drug discovery innovation center, have signed a non-exclusive commercial-use CRISPR license agreement.

Pharmalittle: We’re reading about a CEO change at AbbVie, a long-acting HIV drug, and more

Rise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on

February 21, 2024

‘Serious liver injury’ cases lead FDA to call for monitoring of Ocaliva patients

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

December 13, 2024

Learning from loss: US covid-19 experience charts path for future public health

Ahead of the 2024 US presidential election, The BMJ today launches a forward-looking series that highlights the lessons that can be learned from the US’s

January 30, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.